HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical, microbiological, and immunological aspects of healthy versus peri-implantitis tissue in full arch reconstruction patients: a prospective cross-sectional study.

AbstractBACKGROUND:
Due to the world-wide increase in treatments involving implant placement, the incidence of peri-implant disease is increasing. Late implant failure is the result of the inability to maintain osseointegration, whose most important cause is peri-implantitis. The aim of this study was to analyze the clinical, microbiological, and immunological aspects in the peri-implant sulcus fluid (PISF) of patients with healthy dental implants and patients with peri-implantitis.
METHODS:
PISF samples were obtained from 24 peri-implantitis sites and 54 healthy peri-implant sites in this prospective cross-sectional study. The clinical parameters recorded were: modified gingival index (mGI), modified plaque index (mPI) and probing pocket depth (PPD). The periodontopathogenic bacteria Tannerella forsythia, Treponema denticola and Porphyromonas gingivalis were evaluated, together with the total bacterial load (TBL). PISF samples were analyzed for the quantification of Interleukin (IL)-8, IL-1β, IL-6, IL-10 and Tumor Necrosis Factor (TNF)-α using flow cytometry (FACS).
RESULTS:
The mGI and PPD scores in the peri-implantitis group were significantly higher than the healthy group (p < 0.001). A total of 61.5% of the patients with peri-implantitis had both arches rehabilitated, compared with 22.7% of patients with healthy peri-implant tissues; there was no implant with peri-implantitis in cases that received mandibular treatment exclusively (p < 0.05). Concentrations of Porphyromonas gingivalis (p < 0.01), association with bacteria Porphyromonas gingivalis and Treponema denticola (p < 0.05), as well as the TBL (p < 0.05) are significantly higher in the peri-implantitis group. IL-1β (p < 0.01), IL-6 (p < 0.01), IL-10 (p < 0.05) and TNF-α (p < 0.01) are significantly higher at the sites with peri-implantitis compared to healthy peri-implant tissue, while IL-8 did not increase significantly.
CONCLUSION:
The results of the present study involving a limited patient sample suggest that the peri-implant microbiota and which dental arch was rehabilitated involved could contribute to bone loss in peri-implantitis. A significant relationship is observed between the concentration of cytokines (interleukins 1β, 6 and 10 and TNF-α) and the inflammatory response in peri-implantitis tissue.
AuthorsJavier Ata-Ali, Antonio Juan Flichy-Fernández, Teresa Alegre-Domingo, Fadi Ata-Ali, Jose Palacio, Miguel Peñarrocha-Diago
JournalBMC oral health (BMC Oral Health) Vol. 15 Pg. 43 (Apr 01 2015) ISSN: 1472-6831 [Electronic] England
PMID25888355 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • CXCL8 protein, human
  • Dental Implants
  • IL10 protein, human
  • IL6 protein, human
  • Interleukin-1beta
  • Interleukin-6
  • Interleukin-8
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
Topics
  • Aged
  • Bacterial Load
  • Bacteroides (isolation & purification)
  • Cross-Sectional Studies
  • Dental Arch (pathology)
  • Dental Implants
  • Dental Plaque Index
  • Dental Prosthesis, Implant-Supported
  • Female
  • Gingival Crevicular Fluid (chemistry, immunology, microbiology)
  • Humans
  • Interleukin-10 (analysis)
  • Interleukin-1beta (analysis)
  • Interleukin-6 (analysis)
  • Interleukin-8 (analysis)
  • Male
  • Middle Aged
  • Peri-Implantitis (immunology, microbiology, pathology)
  • Periodontal Index
  • Periodontal Pocket (immunology, microbiology, pathology)
  • Periodontium (anatomy & histology, immunology, microbiology)
  • Porphyromonas gingivalis (isolation & purification)
  • Prospective Studies
  • Treponema denticola (isolation & purification)
  • Tumor Necrosis Factor-alpha (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: